Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
Dr Reddy's Laboratories is setting up two special economic zones -- one each at Hyderabad and Visakhapatnam in Andhra Pradesh.
Dr Reddy's Laboratories hopes to become a true drug discovery company in the near future, said chairman K Anji Reddy and chief executive officer GV Prasad at the 24th annual general body meeting in Hyderabad on Tuesday.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances